Core Scientific (CORZ) has drawn fresh attention after appointing technology veteran Mark W. Adams to its Board of Directors, expanding the board to seven members and adding extensive AI infrastructure and semiconductor experience.

At a share price of $19.76, Core Scientific has seen its short term share price return soften, with a 7 day move down 13.37% and a 30 day decline of 15.88%. However, its year to date share price return of 23.58% and 1 year total shareholder return of 30.77% indicate momentum that has built over a longer window as investors react to developments like the appointment of Mark W. Adams and other business updates.

If you are looking at Core Scientific in the context of wider AI infrastructure activity, it can also be useful to see what else is moving in the space by checking the 57 AI infrastructure stocks.

After a sharp pullback, but with Core Scientific still trading well below consensus analyst targets, the gap between price and expectations is wide. Is that a sign of opportunity, or a warning that market caution on this stock is warranted?

Most Popular Narrative: 44.9% Undervalued

Against the last close of $19.76, the most popular Core Scientific narrative anchors on a fair value of $35.86, creating a sizeable gap that hinges on long term AI infrastructure assumptions.

The AMD agreement supports Core Scientific’s shift away from bitcoin mining toward AI infrastructure services, with leased power capacity at roughly 1.1 GW as of mid 2026 and potential contracted revenue cited at more than US$24b, while current billing for 437 MW was tied to about US$635m in annualized colocation GAAP revenue. Source: recent AMD partnership announcement.

Read the complete narrative. Read the complete narrative.

If you want to understand why this valuation leans so heavily on future AI power leases and margin expansion assumptions, the key lies in how fast revenues and earnings are projected to scale against that long dated, pre committed capacity. It is useful to examine which growth, profitability and discount rate inputs contribute most to that $35.86 fair value.

Result: Fair Value of $35.86 (UNDERVALUED)

However, Core Scientific’s reliance on large AI contracts like CoreWeave and AMD, along with ongoing losses and recent Chapter 11 restructuring, could still derail this positive narrative.

Another View on Core Scientific’s Valuation

The analyst narrative frames Core Scientific as 44.9% undervalued, based on long term earnings forecasts and a $35.86 fair value. Yet the current P/S ratio of 14.4x is far above the US Software industry at 3.8x, the peer average at 3.9x, and even the 7.1x fair ratio. That gap suggests investors are already paying a premium. Is this justified by future AI contracts, or does it leave less room if expectations are not met?

See what the numbers say about this price in our valuation breakdown. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern around Core Scientific, it makes sense to move quickly and review the numbers yourself. To weigh both the upside potential and the key issues that could hold the stock back, start with the 1 key reward and 3 important warning signs.

Looking For More Investment Ideas Beyond Core Scientific?

If you are serious about finding the next opportunity after Core Scientific, do not stop here. The Simply Wall Street Screener can surface ideas you might otherwise miss.

• Target potential mispricing by reviewing companies that appear attractively valued on key metrics using the 49 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with robust payouts and yields through the 8 dividend fortresses.
• Prioritize capital preservation by checking companies with lower overall risk profiles in the 85 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.